Moderna and Merck have announced that late-stage trials of a personalised mRNA cancer vaccine for the treatment of melanoma have yielded positive results. The companies stated that the treatment reduced the risk of melanoma recurrence or spread when used in conjunction with Merck’s immunotherapy drug Keytruda. Notably, Keytruda is already widely used to treat melanoma and several other cancers. This…
Tag: Merck
-
Aspen HIV Prevention Pill Deal Expands African Access
Aspen Pharmacare will become a major African supplier of Merck’s experimental monthly HIV prevention pill, alimatravir. The agreement depends on the medicine successfully completing clinical trials and receiving regulatory approval. Merck granted voluntary licenses to seven generic drug manufacturers, including the South African company, to produce and distribute lower-cost versions of the medicine. The drug also goes by its development…
-
mRNA Vaccines Show Promise in Personalised Therapy
Cancer vaccines based on mRNA technology are showing encouraging results against some of the world’s hardest-to-treat cancers, including melanoma, pancreatic cancer and glioblastoma. The same technology used to develop COVID-19 vaccines at record speed is now being tested to train the immune system to recognise and destroy cancer cells. In addition, researchers say the field has become one of the…
-
Immunotherapy for Cancer and Early-Stage Success
Ground-breaking advancements in immunotherapy are poised to transform cancer care. New data reveal the effectiveness of these immune-boosting drugs in treating a wider range of cancers at their earlier stages. Previously established as life-extending treatments for advanced diseases, drugs such as Bristol Myers Squibb’s Opdivo, AstraZeneca’s Imfinzi, and Roche’s Tecentriq are now demonstrating significant promise. They are preventing recurrence and…